Get the latest news, insights, and market updates on CDNA (CareDx, Inc). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets
BRISBANE, Calif., March 05, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the launch of VANTx™, an AI‑powered, cloud‑native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real‑world ev Mar 5, 2026 - $CDNA
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., February 27, 2026--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. Feb 27, 2026 - $CDNA
CareDx Q4 Earnings Call Highlights
CareDx (NASDAQ:CDNA) reported fourth-quarter and full-year 2025 results alongside a detailed outlook for 2026, highlighting growth across its testing services, patient and digital solutions, and lab products businesses. Management also discussed continued improvements in revenue cycle management, pr Feb 25, 2026 - $CDNA
CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Feb 25, 2026 - $CDNA
CareDx (CDNA) Q4 Earnings Miss Estimates
CareDx (CDNA) delivered earnings and revenue surprises of -48.94% and +5.66%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 25, 2026 - $CDNA
CareDx (CDNA) Q4 2025 Earnings Call Transcript
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements are based upon current estimates and various assumptions. Feb 24, 2026 - $CDNA
CareDx: Q4 Earnings Snapshot
The Brisbane, California-based company said it had a loss of 8 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, were 12 cents per share. The molecular diagnostics company posted revenue of $108.4 million in the period, which beat Street forecasts. Feb 24, 2026 - $CDNA
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
BRISBANE, Calif., February 24, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2025. Feb 24, 2026 - $CDNA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple